The Company no longer has the ability to sell its aXOpore® products in Singapore under a
special access framework, which is has done for the past nine months. As such, the financial
impact of the Singapore regulatory approval is estimated to be around 30-50% of the
Company’s revenues from the Singapore region in the past nine months of up to SGD90k. The
Company has no past sales history in Vietnam and the financial impact is unknown.
Is this negative or positive?
The Company no longer has the ability to sell its aXOpore®...
Add OSX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.060(17.7%) |
Mkt cap ! $4.131M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 44.5¢ | 32.0¢ | $293.2K | 761.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25641 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 34392 | 2 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
40.0¢ |
Change
0.060 ( 2.44 %) |
||||
| Open | High | Low | Volume | ||
| 39.0¢ | 43.5¢ | 37.0¢ | 48054 | ||
| Last updated 15.37pm 26/04/2024 ? | |||||
| OSX (ASX) Chart |